07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Molecular Targeting Technologies, Medical College of Wisconsin deal

The college granted Molecular Targeting an exclusive license to a patent covering the synthesis and characterization of 99mTc-Duramycin for the non-invasive imaging of dead and dying cells. Molecular Targeting will develop 99mTc-Duramycin to diagnose acute...